Attached files

file filename
EX-99 - EXHIBIT 99.1 - RESPONSE BIOMEDICAL CORPrpbif20130312_8kex99-1.htm

 



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549


 FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

 

March 11, 2013


RESPONSE BIOMEDICAL CORP.

(Exact name of registrant as specified in its charter)

 

Vancouver, British Columbia, Canada

 

000-50571

 

98 -1042523

(State or other jurisdiction of incorporation)

 

(Commission File Number)

 

(IRS Employer Identification No.)

 

1781 - 75th Avenue W.

Vancouver, British Columbia, Canada V6P 6P2

(Address of principal executive offices, including zip code)

 

(604) 456-6010

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



 

 
 

 

  

Item 2.02     Results of Operation and Financial Condition

 

On March 11, 2013, Response Biomedical Corp. issued a press release announcing financial results for its fourth quarter and fiscal year ended December 31, 2012. The information contained in the press release is incorporated herein by reference and furnished as Exhibit 99.1

 

The information in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, or the Exchange Act, except to the extent that we specifically incorporate it by reference. 

 

Item 9.01     Financial Statements and Exhibits.

 

(d)    Exhibits.

 

Exhibit Number

 

Description

99.1

 

Press release of Response Biomedical Corp. dated March 11, 2013.

     
     

 

 

 
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 

   

RESPONSE BIOMEDICAL CORP.

     
 

By:  

/s/William J. Adams

 
   

William J. Adams

Chief Financial Officer

 

Date: March 12, 2013

 

 

 
 

 

 

EXHIBIT INDEX

 

 

Exhibit Number

 

Description

99.1

 

 

Press release of Response Biomedical Corp. dated March 11, 2013.